Eli Lilly and Company (LILY34) — Cash Flow Reinvestment Rate
Eli Lilly and Company (LILY34) has a Cash Flow Reinvestment Rate of 0.53x as of March 2026, reinvesting R$2.83 Billion (capex R$2.53 Billion plus investments R$-297.00 Million) from operating cash flow of R$5.33 Billion. See LILY34 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eli Lilly and Company Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for Eli Lilly and Company across 12 annual periods. For the full cash flow conversion analysis, see LILY34 cash flow metrics.
Annual Cash Flow Reinvestment Rate for Eli Lilly and Company (2014–2025)
Year-by-year capital reinvestment analysis for Eli Lilly and Company. See LILY34 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (BRL) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | R$11.17 Billion | R$16.81 Billion | R$10.85 Billion | ▼ -66.9% |
| 2024 | 2.01x | R$17.71 Billion | R$8.82 Billion | R$8.40 Billion | ▲ +8.7% |
| 2023 | 1.85x | R$10.55 Billion | R$5.71 Billion | R$5.88 Billion | ▲ +523.4% |
| 2022 | 0.30x | R$2.10 Billion | R$7.08 Billion | R$1.85 Billion | ▲ +45.7% |
| 2021 | 0.20x | R$1.48 Billion | R$7.26 Billion | R$1.31 Billion | ▼ -48.1% |
| 2020 | 0.39x | R$2.55 Billion | R$6.50 Billion | R$2.03 Billion | ▲ +4.7% |
| 2019 | 0.37x | R$1.81 Billion | R$4.84 Billion | R$1.35 Billion | ▼ -74.6% |
| 2018 | 1.47x | R$8.13 Billion | R$5.52 Billion | R$3.02 Billion | ▲ +203.1% |
| 2017 | 0.49x | R$2.73 Billion | R$5.62 Billion | R$2.16 Billion | ▼ -44.3% |
| 2016 | 0.87x | R$4.23 Billion | R$4.85 Billion | R$1.09 Billion | ▲ +16.1% |
| 2015 | 0.75x | R$2.23 Billion | R$2.96 Billion | R$1.07 Billion | ▼ -30.0% |
| 2014 | 1.07x | R$4.79 Billion | R$4.46 Billion | R$1.16 Billion | — |